ADC Therapeutics SA
NYSE:ADCT

ADC Therapeutics SA (NYSE:ADCT)

Add ADCT to Watchlist

Income Statement

-
Revenue
1 Year
N/A
3 Years
N/A
5 Years
N/A
-
Gross Proft
1 Year
N/A
3 Years
N/A
5 Years
N/A
-219.3M
Operating Income
1 Year
-84%
3 Years
-34%
5 Years
N/A
-246.3M
Net Income
1 Year
-111%
3 Years
-40%
5 Years
N/A
Currency: USD
Dec-2020 Dec-2019 Dec-2018 Dec-2017
Revenue
Revenue
0
-
2
+105%
1
-37%
2
-
Operating Income
Operating Expenses
(219)
(122)
(127)
(93)
Selling, General & Administrative
(77)
(14)
(9)
(8)
Research & Development
(140)
(106)
(118)
(85)
Depreciation & Amortization
(2)
(2)
(1)
(0)
Operating Income
(219)
-84%
(119)
+5%
(126)
-37%
(92)
-
Pre-Tax Income
Interest Income Expense
(27)
2
3
2
Non-Reccuring Items
0
0
(0)
0
Total Other Income
1
2
0
0
Pre-Tax Income
(246)
-112%
(116)
+6%
(123)
-37%
(90)
-
Net Income
Tax Provision
(0)
(1)
(0)
(0)
Income from Continuing Operations
(246)
(116)
(123)
(90)
Net Income (Common)
(246)
-111%
(116)
+5%
(123)
-37%
(90)
-

Balance Sheet

514M
Assets
1 Year
273%
3 Years
24%
5 Years
N/A
178M
Liabilities
1 Year
572%
3 Years
98%
5 Years
N/A
336M
Equity
1 Year
202%
3 Years
10%
5 Years
N/A
Currency: USD
Dec-2020 Dec-2019 Dec-2018 Dec-2017
Assets
Cash & Cash Equivalents
439
116
139
263
Cash Equivalents
439
116
139
263
Total Receivables
1
1
2
2
Accounts Receivables
0
0
0
1
Other Receivables
0
1
2
1
Other Current Assets
10
6
2
1
Total Current Assets
451
123
142
265
PP&E Net
5
6
2
1
PP&E Gross
5
6
2
1
Accumulated Depreciation
4
3
1
1
Intangible Assets
10
8
7
5
Long-Term Investments
48
0
0
0
Other Long-Term Assets
0
0
0
0
Total Assets
514
+273%
138
-9%
151
-45%
272
-
Liabilities
Accounts Payable
5
3
7
8
Accrued Liabilities
12
6
5
4
Short-Term Debt
0
0
0
0
Current Portion of Long-Term Debt
5
1
0
0
Other Current Liabilities
19
10
11
9
Total Current Liabilities
40
20
22
21
Long-Term Debt
37
4
0
0
Other Liabilities
101
3
2
2
Total Liabilities
178
+572%
27
+9%
24
+7%
23
-
Equity
Common Stock
6
4
0
0
Retained Earnings
652
443
326
204
Additional Paid In Capital
981
550
452
452
Treasury Stock
0
0
0
0
Other Equity
0
0
0
0
Total Equity
336
+202%
111
-12%
126
-49%
249
-
Total Liabilities & Equity
514
+273%
138
-9%
151
-45%
272
-
Shares Outstanding
Common Shares Outstanding
76.7M
76.7M
76.7M
76.7M

Cash Flow Statement

-168.7M
Operating Cash Flow
1 Year
-39%
3 Years
-31%
5 Years
N/A
-2.8M
Capital Expenditures
1 Year
-31%
3 Years
4%
5 Years
N/A
-171.5M
Free Cash Flow
1 Year
-39%
3 Years
-30%
5 Years
N/A
Currency: USD
Dec-2020 Dec-2019 Dec-2018 Dec-2017
Operating Cash Flow
Net Income
(246)
(116)
(123)
(90)
Depreciation & Amortization
2
2
0
0
Other Non-Cash Items
64
0
(0)
0
Cash Taxes Paid
0
0
0
0
Cash Interest Paid
2
0
0
0
Change in Working Capital
12
(7)
1
14
Cash from Operating Activities
(169)
-39%
(122)
0%
(121)
-62%
(75)
-
Investing Cash Flow
Capital Expenditures
(3)
(2)
(2)
(3)
Other Items
(0)
(0)
(0)
(0)
Cash from Investing Activities
(3)
-26%
(2)
+10%
(3)
+23%
(3)
-
Financing Cash Flow
Net Issuance of Common Stock
433
102
(0)
197
Net Issuance of Debt
62
(1)
0
0
Cash from Financing Activities
495
+392%
101
-
(0)
-
197
-
Change in Cash
Effect of Foreign Exchange Rates
0
0
(0)
0
Net Change in Cash
324
-
(23)
+81%
(124)
-
119
-